In an adult with type 2 diabetes, eGFR ≥30 mL/min/1.73 m², and microalbuminuria while on a maximally tolerated ACE inhibitor or ARB, should I start finerenone (Kerendia)?

Yes, start finerenone (Kerendia) in this patient with type 2 diabetes, eGFR ≥30 mL/min/1.73 m², and microalbuminuria on maximally tolerated ACE inhibitor or ARB therapy.

The 2022 KDIGO and ADA consensus guidelines explicitly recommend adding a nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) with proven kidney and cardiovascular benefit for patients with type 2 diabetes, eGFR ≥25 mL/min/1.73 m², normal serum potassium, and albuminuria (ACR ≥30 mg/g) despite maximum tolerated RAS inhibitor therapy 1.

Rationale for Adding Finerenone

Your patient meets all criteria for finerenone initiation:

• Type 2 diabetes with CKD
• Persistent microalbuminuria (ACR ≥30 mg/g) despite maximally tolerated ACE inhibitor or ARB
• eGFR ≥30 mL/min/1.73 m² (guideline threshold is ≥25)
• This represents residual cardiorenal risk requiring additional intervention

The guidelines emphasize that finerenone provides additive cardiorenal protection beyond standard RAS blockade, targeting inflammation and fibrosis through mineralocorticoid receptor antagonism 1. This is not simply optimizing existing therapy—it's adding a complementary mechanism of action.

Evidence Base

The FIDELIO-DKD and FIGARO-DKD trials demonstrated that finerenone significantly reduces:

• Kidney outcomes: Composite of kidney failure, sustained ≥40% eGFR decline, or renal death (HR 0.82 in FIDELIO-DKD) 2
• Cardiovascular outcomes: CV death, nonfatal MI, nonfatal stroke, or heart failure hospitalization (HR 0.87 in FIGARO-DKD) 3
• Albuminuria: Consistent UACR reductions across all patient subgroups 4, 5, 6

These benefits occurred on top of maximally tolerated ACE inhibitor or ARB therapy (99.8% of trial participants were on RAS blockade) 2.

Practical Initiation Protocol

Pre-initiation Requirements

Check serum potassium and confirm:

• Potassium ≤5.0 mEq/L (FDA label) or ≤4.8 mEq/L (trial criteria) 1, 2
• eGFR ≥25 mL/min/1.73 m² 1

Dosing Algorithm

For eGFR 25-60 mL/min/1.73 m²: Start 10 mg once daily 1, 2 For eGFR >60 mL/min/1.73 m²: Start 20 mg once daily 1, 2

Your patient with eGFR ≥30 would start at 10 mg daily if eGFR is 30-60, or 20 mg daily if eGFR >60.

Monitoring Schedule

• Week 4: Check potassium and eGFR after initiation 1, 2
• Ongoing: Monitor potassium regularly during maintenance therapy
• Uptitration: If potassium <4.8 mEq/L and tolerating well, uptitrate to 20 mg daily 1

Potassium Management Algorithm

• K <5.0 mEq/L: Continue current dose or uptitrate
• K 5.0-5.5 mEq/L: Maintain current dose, monitor closely
• K >5.5 mEq/L: Withhold finerenone; restart at 10 mg when K <5.0 mEq/L 1, 2

Critical Safety Considerations

Hyperkalemia is the primary concern but is manageable:

• Occurred in 14% of finerenone patients vs 6.9% placebo across trials 2
• Led to hospitalization in only 0.9% of patients 2
• Caused permanent discontinuation in 1.7% vs 0.6% placebo 2

Do NOT combine with strong CYP3A4 inhibitors (contraindicated) 2. Common culprits include ketoconazole, itraconazole, clarithromycin, and ritonavir.

More frequent monitoring needed if:

• Concurrent potassium-sparing diuretics
• NSAIDs
• Potassium supplements
• Other medications that increase potassium 2

Why This Matters for Your Patient

Microalbuminuria represents early kidney damage and significantly elevated cardiovascular risk. The combination of ACE inhibitor/ARB + finerenone provides dual RAS pathway blockade (angiotensin vs mineralocorticoid receptors) without the dangers of combining ACE inhibitor + ARB 1.

Real-world data confirms that finerenone reduces albuminuria even in patients already on RAS inhibitors, with greater effect when combined versus finerenone alone 4. The antialbuminuric effect mediates much of the cardiorenal benefit 7.

Common Pitfalls to Avoid

1. Don't wait for macroalbuminuria: Guidelines recommend finerenone for any level of persistent albuminuria ≥30 mg/g 1
2. Don't stop at eGFR <25: Once initiated, continue finerenone even if eGFR falls below 25 as long as potassium is acceptable 1
3. Don't immediately discontinue for mild hyperkalemia: Use potassium-lowering strategies (dietary modification, diuretic adjustment, potassium binders) rather than stopping finerenone unless K >5.5 mEq/L 1, 2
4. Don't forget SGLT2 inhibitor: If not already prescribed, your patient should also be on an SGLT2 inhibitor (separate 1A recommendation) 8. Finerenone and SGLT2 inhibitors have complementary mechanisms and can be safely combined 5, 6

The evidence is clear: adding finerenone to maximally tolerated RAS blockade reduces both kidney disease progression and cardiovascular events in patients exactly like yours, with an acceptable safety profile when properly monitored 1, 3.